# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0189 |
| Population Package | PP-0189 |
| Title | Genomic Test Results / How to Read a Molecular Report |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |

---

# Layer 1 — Content QA

| Criterion | Result | QA Note |
|---|---|---|
| Single educational question | PASS | The package answers how to read and understand a genomic/molecular report. |
| Scope respected | PASS | Report literacy is central; treatment and detailed testing remain excluded. |
| Complete coverage | PASS | Test, specimen, scope, findings, interpretation, limitations, actionability and clinical context are covered. |
| Internal consistency | PASS | Definitions and boundaries are consistent across CKO, KP and Evidence Package. |
| Logical organization | PASS | Content follows test → specimen → scope → finding → interpretation → relevance → limitation → context. |
| Knowledge blocks complete | PASS | Independent patient-facing blocks are used throughout. |
| Common misconceptions addressed | PASS | Negative results, VUS, actionability, germline findings and discordance are addressed. |
| Knowledge Graph complete | PASS | Prerequisite, related and downstream PPs are defined. |
| Adjacent PP overlap controlled | PASS | Explicit ownership boundaries prevent duplication with PP-0187, PP-0181–0186, PP-0190 and PP-0191. |

---

# Layer 2 — Clinical QA

| Criterion | Result | QA Note |
|---|---|---|
| Scientifically accurate within source-supported scope | PASS | Claims are anchored to NCCN, ESMO-ASCO, NCI and ACS project materials. |
| Consistent with NCCN gastric-cancer guidance | PASS | NGS, biomarker and ctDNA statements follow the supplied NCCN materials. |
| Consistent with ESMO-ASCO genomic-testing framework | PASS | Assay types, alteration categories, pre/post-analytic variables and clinical context are represented conservatively. |
| Consistent with NCI genetics guidance | PASS | VUS, multigene testing and possible germline implications are represented within scope. |
| Consistent with NCI patient treatment context | PASS | Molecular findings are not converted into automatic treatment instructions. |
| Consistent with ACS patient education | PASS | Biomarker-linked treatment examples are used only as context. |
| No unsupported clinical claim | PASS | General principles are framed conservatively and source traceability is documented. |
| No unsafe medical advice | PASS | No individualized treatment, diagnosis, or treatment-change instruction is given. |
| Negative-result interpretation appropriately qualified | PASS | “Negative” is tied to assay scope and limitations rather than equated with genomic normality. |
| VUS appropriately qualified | PASS | VUS is described as uncertainty, not as an actionable or harmful finding. |
| Germline implications appropriately qualified | PASS | Tumor findings are not treated as proof of inherited disease. |
| Actionability appropriately qualified | PASS | “Actionable” is presented as context-dependent rather than automatic treatment eligibility. |

---

# Layer 3 — Educational QA

| Criterion | Result | QA Note |
|---|---|---|
| Plain language | PASS | Technical terms are explained at first use. |
| Patient-friendly wording | PASS | Content avoids unnecessary jargon and uses question-based headings. |
| Learning objectives satisfied | PASS | Objectives map directly to the clinical knowledge blocks. |
| Logical learning progression | PASS | The report-reading sequence is explicit and reusable. |
| Common misconceptions addressed | PASS | Dedicated misconception section included. |
| Practical usefulness | PASS | Patient-facing questions for the care team are included. |
| Appropriate uncertainty communication | PASS | VUS, negative results, failed testing and actionability are carefully distinguished. |
| Avoids overpromising | PASS | No claim that molecular testing can answer every clinical question. |
| Encourages clinician discussion | PASS | Package repeatedly directs individualized interpretation to the cancer care team. |
| Appropriate educational boundary | PASS | No attempt to interpret an individual's actual report. |

---

# Layer 4 — Governance QA

| Criterion | Result | QA Note |
|---|---|---|
| CKO completed | PASS | 01_CKO.md produced. |
| Knowledge Passport completed | PASS | 02_KNOWLEDGE_PASSPORT.md produced. |
| Evidence Package completed | PASS | 03_PRIMARY_EVIDENCE_PACKAGE.md produced. |
| QA Report completed | PASS | This artifact completed. |
| Gold specification followed | PASS | Four-artifact structure preserved. |
| Approved Decision Batch respected | PASS | Locked PP-0189 scope is implemented without reopening decisions. |
| Source-first rule respected | PASS | Relevant project Source Files were searched and used. |
| Gold reference depth preserved | PASS | Artifact content is intentionally full-depth rather than compacted. |
| Artifact naming compliant | PASS | Standard four artifact names used. |
| Versioning compliant | PASS | Semantic version 1.0.0 used. |
| Knowledge Graph complete | PASS | Prerequisite, related and downstream links included. |
| Boundary ownership preserved | PASS | Core / Supporting / Explicitly Excluded / Delegated-to PP structure used. |
| Repository-ready structure | PASS | Four Markdown artifacts packaged in one PP directory and ZIP. |

---

# Clinical Safety Review

| Item | Result | QA Note |
|---|---|---|
| No individualized treatment recommendation | PASS | Report literacy only. |
| No instruction to start/stop/change treatment | PASS | Explicitly excluded. |
| No individualized prognosis | PASS | Explicitly excluded. |
| No individualized variant interpretation | PASS | Dedicated interpretation packages retain ownership. |
| No unsupported biomarker threshold | PASS | Detailed thresholds delegated. |
| No universal claim that NGS replaces other testing | PASS | NCCN hierarchy preserved. |
| No claim that negative means absence of all mutations | PASS | Negative-result limitation explicitly explained. |
| No claim that tumor finding equals inherited finding | PASS | Germline follow-up appropriately separated. |
| No claim that actionable equals treatment eligibility | PASS | Context dependence explicitly stated. |
| Appropriate referral to clinical team | PASS | Patient questions and clinical-context sections included. |

---

# Educational Boundary Review

The Population Package successfully remains within the locked educational boundary.

## Included

- Understanding what a molecular/genomic report is.
- Understanding test and specimen context.
- Understanding assay scope.
- Recognizing molecular findings.
- Understanding detected/not-detected and uncertain results.
- Understanding actionability at a high level.
- Understanding limitations and clinical context.
- Recognizing possible germline implications.
- Preparing questions for the care team.

## Explicitly Excluded

- NGS laboratory methodology.
- Sequencing and bioinformatics.
- Detailed variant interpretation/classification.
- Individual biomarker testing/scoring.
- Detailed ctDNA biology.
- Germline testing algorithms.
- Treatment selection.
- Individualized prognosis.
- Individualized interpretation of an actual patient report.

The **Atomic Knowledge Principle** is preserved.

---

# Boundary QA

**Core =** molecular-report literacy, including test context, specimen context, assay scope, reported molecular findings, common result terminology, high-level clinical relevance/actionability, limitations, clinical-context integration, and patient-facing interpretation questions.

**Supporting =** tissue-versus-liquid context, tumor cellularity, assay limitations, discordance, possible germline implications, molecular tumor board concept, and clinical-trial relevance.

**Explicitly Excluded =** detailed NGS methodology, sequencing/bioinformatics, variant calling, detailed variant interpretation/classification, individual biomarker testing/scoring, detailed ctDNA biology, germline testing algorithms, treatment selection, individualized prognosis, and individualized report interpretation.

**Delegated-to PP =** PP-0107, PP-0108, PP-0110, PP-0111, PP-0178, PP-0179, PP-0180, PP-0181–PP-0188, PP-0190, PP-0191, relevant hereditary/genetic-testing PPs, ctDNA/liquid-biopsy PPs, and downstream treatment PPs.

---

# Evidence Traceability QA

The major evidence claims are traceable to the project Source Materials:

- **NCCN v2.2026** — gastric-cancer biomarker testing, NGS, molecular events, ctDNA/liquid biopsy.
- **ESMO-ASCO 2023** — genomic assay categories, genomic alteration classes, pre-/post-analytic variables, clinical context, germline implications.
- **NCI Cancer Genetics PDQ** — VUS, multigene testing, incidental germline findings and counselling.
- **NCI Stomach Cancer Treatment** — patient-facing biomarker/treatment context and multidisciplinary decision-making.
- **ACS Stomach Cancer / Immunotherapy for Stomach Cancer** — patient-facing biomarker-treatment examples.

No unsupported external evidence was introduced into the Evidence Package.

---

# Gold Artifact Completeness Check

| Artifact | Present | Structural QA |
|---|---|---|
| 01_CKO.md | PASS | Metadata, objectives, scope, knowledge blocks, misconceptions, key messages, Knowledge Graph, revision history present |
| 02_KNOWLEDGE_PASSPORT.md | PASS | Identity, classification, runtime relevance, graph, scope, sources, evidence classification, governance and versioning present |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | PASS | Clinical question, scope, sources, hierarchy, evidence matrix, claims, gaps, delegation, traceability and boundary verification present |
| 04_QA_REPORT.md | PASS | Four QA layers, clinical safety, boundary, traceability and final decision present |

---

# Final Quality Decision

# PASS

PP-0189 satisfies the locked **FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.0** and the approved/locked PP-0189 Decision Batch.

The package maintains the intended architecture:

**NGS / Molecular Testing**

↓

**Molecular Findings / Report**

↓

**PP-0189 — Genomic Test Results / How to Read a Molecular Report**

↓

**Biomarker-Specific Clinical Application**

↓

**Treatment Population Packages**

The package does not duplicate the substantive ownership of NGS methodology, dedicated biomarker testing, variant interpretation/classification, germline testing, or treatment selection.

---

# Reviewer Notes

PP-0189 functions as a **report-literacy bridge node** in the molecular oncology knowledge graph.

Its main value is not to add another molecular-testing methodology package. Its value is to provide a structured patient-facing explanation of how to move from a technically complex laboratory document to an appropriately contextualized clinical conversation.

The package deliberately preserves uncertainty and limitations. In particular, it avoids three unsafe shortcuts:

1. **Detected alteration → automatic treatment.**
2. **Negative result → absence of all molecular abnormalities.**
3. **Tumor finding → inherited genetic finding.**

These safeguards are central to the Gold educational boundary.

---

# Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
